81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML

ABSTRACT IMPACT: This work will help to understand a novel therapeutic approach to a common type of acute myeloid leukemia. OBJECTIVES/GOALS: FMS-like tyrosine kinase 3 (or FLT3) mutations occur in ˜30% of acute myeloid leukemia (AML) cases. FLT3 tyrosine kinase domain (TKD) mutations are particular...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, LaQuita, Melgar, Katelyn, Hoyt, Scott, Wunderlich, Mark, O’Brien, Eric, Perentesis, John, Thomas, Craig, Starczynowski, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Precision Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828039/
http://dx.doi.org/10.1017/cts.2021.658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828039/
http://dx.doi.org/10.1017/cts.2021.658

Ejemplares similares